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Abstract
Background: Dinitrosyl nonheme-iron complexes can appear in cells and tissues overproducing
nitric oxide. It is believed that due to their chemical nature these species may be implicated in
certain pathophysiological events. We studied the possible role of low molecular mass dinitrosyl
iron complexes in the control of noradrenaline release in electrically stimulated rat tail artery.
Results: A model complex, dinitrosyl-iron-thiosulfate (at 1–10 µM) produced a concentration-
dependent enhancement of electrical field stimulated [3H]noradrenaline release (up to 2 fold). At
the same time, dinitrosyl-iron-thiosulfate inhibited neurogenic vasoconstriction, consistent with its
nitric oxide donor properties. A specific inhibitor of cyclic GMP dependent protein kinase, Rp-
8pCPT-cGMPS, partially inhibited the effect of dinitrosyl-iron-thiosulfate on neurogenic
vasoconstriction, but not on [3H]noradrenaline release. Another model complex, dinitrosyl-iron-
cysteine (at 3 µM) elicited similar responses as dinitrosyl-iron-thiosulfate. Conventional NO and
NO+ donors such as sodium nitroprusside, S-nitroso-L-cysteine or S-nitroso-glutathione (at 10
µM) had no effect on [3H]noradrenaline release, though they potently decreased electrically-
induced vasoconstriction. The "false complex", iron(II)-thiosulfate showed no activity.
Conclusions: Low molecular mass iron dinitrosyl complexes can up-regulate the stimulation-
evoked release of vascular [3H]noradrenaline, apparently independently of their NO donor
properties. This finding may have important implications in inflammatory tissues.
Background
Dinitrosyl non-heme iron complexes (DNIC) are intrinsic
nitric oxide (NO)-derived species that can appear in vari-
ous NO overproducing tissues including inflammatory
blood vessels [1,2]. Due to their reactivity, DNIC may
have multiple biologically important targets. [3–8]. There
are high molecular mass (protein-bound) and low molec-
ular mass DNIC, paramagnetic and diamagnetic DNIC
[9]. The low molecular mass DNIC are much more pow-
erful nitrosative agents than NO or the low molecular
weight S-nitrosothiols [5,9]. Depending on the micro-en-
vironment, DNIC can provide at least two types of nitro-
sative modification of proteins, forming either protein-S-
nitrosothiols or protein-bound dinitrosyl iron complexes
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[5,9]. Under certain conditions, low molecular mass
DNIC may also serve as NO donors and consequently as
activators of soluble guanylyl cyclase and vasodilators [7].
Nitrosative modification of proteins can lead to a change
of protein function and may have important physiologi-
cal significance [8,10–12]. We have demonstrated recent-
ly, that in neuronal/neurosecretory PC 12 cells, low
molecular mass DNIC specifically activate non-selective
cationic channels and induce membrane depolarisation
[6]. We hypothesised, that low molecular mass DNIC may
also affect the process of neuromediator release, which is
known to be associated with membrane depolarisation
and involves an array of thiol-containing proteins which
are usually sensitive to S-nitrosation [13,14]. To test this
hypothesis, we used the model of the electrical field stim-
ulated rat tail artery in which neither constitutive NO nor
the NO donor SIN-1, influence the release of noradrena-
line [15]. Here we demonstrate for the first time, that the
two model compounds, DNIC-thiosulfate and DNIC-
cysteine up-regulate noradrenaline release in the rat tail
artery.
Results
Low molecular mass DNIC increase [3H]noradrenaline re-
lease
DNIC-thiosulfate (1–10 µM), in a concentration depend-
ent manner, enhanced the electrical field stimulated [3H]
noradrenaline release. This effect showed significance al-
ready at 3 µM DNIC-thiosulfate (Fig. 1). In the same arter-
ies, DNIC-thiosulfate inhibited the stimulation-evoked
vasoconstriction (Fig 1), consistent with its NO donor
properties. DNIC-cysteine (at 3 µM) reproduced both
these effects (Table 1). "The false complex", Fe(II)-thiosul-
fate (10 µM) did not affect either [3H]noradrenaline re-
lease or neurogenic vasoconstriction (Table 1). The
conventional NO and NO+ donors, sodium nitroprusside
(SNP), S-nitroso-L-cysteine (Cys-NO) and S-nitroso-glu-
tathione (GS-NO) (at 10 µM) potently inhibited the neu-
rogenic vasoconstriction, had however no effect on
[3H]noradrenaline release (Table 1). DNIC-thiosulfate
did not change the basal release of [3H]noradrenaline
(b4/b2 ratios: 0.92 and 0.93, 0.91, 0.97, 0.96 for saline
and 0.3 µM, 1 µM, 3 µM, 10 µM DNIC, respectively).
Cyclic GMP-dependent protein kinase does not play a role
The membrane permeable and metabolically stable com-
petitive inhibitor of cyclic GMP-dependent protein kinase
(PKG), Rp-8pCPT-cGMPS (10 µM), did not change the
electrical field stimulated [3H]noradrenaline release and
vasoconstriction in control arteries (Fig. 2). Rp-8pCPT-
cGMPS did not affect the augmentation of [3H]noradren-
aline release caused by DNIC-thiosulfate. At the same
time, Rp-8pCPT-cGMPS, partially but significantly re-
duced the "NO-dependent" inhibitory effect of DNIC-thi-
osulfate on vasoconstriction (Fig 2).
Discussion
The major finding of the present study is that DNIC-thio-
sulfate and DNIC-cysteine, at low micromolar concentra-
tions, stimulate the electrical field-evoked noradrenaline
release in the rat tail artery, while other NO and NO+ do-
nors at these concentrations lack this ability.
During the past 10 years, NO has been recognised as a lo-
cal neuromediator of the central and peripheral nervous
system [16]. The role of NO in the process of noradrena-
line release in vascular tissue is largely contradictory [17–
20]. The contradiction of these results could be in part due
to the involvement of different NO-related species in dif-
ferent experimental models. The interactions of NO with
transitional metals control the reactivity of NO including
nitrosation and/or nitration of different biological targets.
DNIC, bound to different ligands is an example of such an
NO-metal interaction [1–10]. Recently, we have shown
that in neuronal/neurosecretory PC 12 cells, DNIC-thio-
sulfate specifically activates a depolarising cationic inward
current; the mechanism of this activation is cyclic GMP-
independent and involves an attachment of dinitrosyl-
Table 1: Effects of various NO donors on stimulation evoked [3H]noradrenaline release and vasoconstriction in the rat tail arteries
Treatment n S4/S2 ratio
[3H]noradrenaline Vasoconstriction
Control 7 1.08 ± 0.05 1.04 ± 0.06
DNIC-cysteine 3 µM 6 1.31 ± 0.06** 0.25 ± 0.02**
DNIC-thiosulfate 3 µM 6 1.38 ± 0.07** 0.33 ± 0.04**
Fe(II)-thiosulfate 10 µM 6 1.01 ± 0.03 0.92 ± 0.05
SNP 10 µM 7 1.04 ± 0.04 0.27 ± 0.06**
Cys-NO 10 µM 7 1.08 ± 0.06 0.23 ± 0.02**
GS-NO 10 µM 7 1.01 ± 0.03 0.27 ± 0.02**
**P < 0.01 in comparison to control arteries.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/3
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iron moieties to yet unknown protein(s) of the plasma
membrane [6]. To test whether DNIC could affect the neu-
romediator release, we here used the model of the electri-
cally stimulated rat tail artery. An advantage of this model
is that vasoactive concentrations of NO or cyclic GMP an-
alogues have no effect on the noradrenaline release
[15,21]. Thus, the potential NO-dependent effect of DNIC
on noradrenaline release in this model is likely excluded.
Accordingly, in the present study, the conventional NO
donors, SNP, Cys-NO and GS-NO, markedly inhibited
neurogenic vasoconstriction, but did not affect the release
of noradrenaline. In contrast, both DNIC-thiosulfate and
DNIC-cysteine were found to be quite potent stimulators
of the electrically evoked noradrenaline release.
While the mechanism of the augmentation of noradrena-
line release by the low molecular mass DNIC requires fur-
ther investigations, it is clearly NO/cyclic GMP/PKG-
independent. Because our experiments were performed in
the presence of cocaine and since DNIC had no effect on
the basal noradrenaline release, the possible modification
of tissue noradrenaline uptake seems to be excluded. The
process of neuromediator release is an extremely complex
cellular action, which is known to involve several
cysteine-rich proteins [13]. Thus, it is possible that, in
analogy with other thiol-containing proteins [10–12], the
function of these proteins is sensitive to S-nitrosative
modification. Since low molecular mass DNIC were
shown to be much more potent S-nitrosative agents than
low molecular mass S-nitrosothiols and NO [5], this sce-
nario appears to be very likely. The potential role of oxy-
gen radicals and lipid peroxidation in the DNIC action are
less probable since the "false complex", Fe(II)-thiosulfate,
which can accelerate the formation of oxygen radicals,
showed no effect. Moreover, various iron-heme-NO and
iron-nonheme-NO complexes proved to be strong anti-
oxidants [22].
In this study a rather discouraging result was the lack of an
apparent contractile effect of the noradrenaline released
by DNIC. This could be attributed to the limitations of
our experimental model, especially to the intra-luminary
manner of DNIC supply and to the highly oxygenated
conditions favouring oxidation of iron in DNIC and liber-
ation of NO [23]. Thus, it is likely that in our model, NO-
mediated vasodilation masked the vasoconstriction,
which is expected from the DNIC-induced increase of no-
radrenaline release. Previously, we have observed a simi-
lar phenomenon using forskolin, which also produced
Figure 1
Effect of DNIC-thiosulfate on electrical field stimu-
lated [3H]noradrenaline release and vasoconstriction
in the rat tail artery. Four periods (S1–S4) of electrical-
field stimulation were delivered with intervals of 16 min.
DNIC-thiosulfate was added 8 min before S3. The effect of
DNIC-thiosulfate is presented as the ratio of change of
[3H]noradrenaline in the perfusate or change of perfusion
pressure evoked by S4 over S2. Each point represents the
mean ± S.E.M. from 6–7 arteries. * P < 0.05 and ** P < 0.01 in
comparison to control arteries.
Figure 2
Effects of PKG inhibitor, (Rp)-8-pCPT-cGMPS on the
DNIC-thiosulfate-induced vascular effects in the rat
tail artery. The effect of the drugs is presented as the ratio
of change of [3H]noradrenaline or change in perfusion pres-
sure evoked by S4 over S2. Each point represents the mean ±
S.E.M. from 6–7 arteries. * P < 0.01 in comparison to control
arteries; # P < 0.01 in comparison to arteries treated with
DNIC-thiosulfate alone.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/3
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vasodilation despite a marked stimulatory effect on the re-
lease of noradrenaline [24]. Nevertheless, we believe that
our findings are not only a curious pharmacological phe-
nomenon, but also may be of pathophysiological impor-
tance. It is likely, that the loci of endogenous DNIC
formation could be critical for the functional net result of
DNIC action. Of note, DNIC species are not as easily dif-
fusible as free NO, thus a concentration gradient in cells/
tissues could be expected.
The concentration of protein-bound DNIC (which is in
equilibrium with low molecular mass DNIC) in inflam-
matory tissue may be as high as 100 µM [5]. Since low
molecular weight DNIC have a pronounced effect on no-
radrenaline release already at low micromolar concentra-
tions, the present findings may have pathophysiological
implications. Recently, the tunica adventitia and its po-
tential impact on blood vessel function attracted much at-
tention [25]. Specifically in endotoxin-exposed rat aorta,
the adventitia was recognised as the major site of induci-
ble NO synthase expression and DNIC production [2].
Thus, in the inflammatory blood vessels, the generation of
DNIC may occur in close proximity to (or even within)
the sympathetic nerve endings. Therefore, one can specu-
late that DNIC, under these circumstances, may unexpect-
edly contribute to vascular contraction. Additionally,
because catecholamines are known to have a trophic effect
on the vascular wall [26], the DNIC-mediated increase of
noradrenaline release may contribute to the thickening of
inflammatory blood vessels. A recent study in patients
with coronary artery disease suggests, that chelatable non-
heme iron interacts with endothelial NO and thus con-
tributes to endothelial dysfunction [27]. Whether this
interaction results in the generation of DNIC-like com-
plexes, which in turn may affect the release of catecho-
lamines, is an intriguing question.
Conclusion
Low molecular mass iron dinitrosyl complexes augment
the electrical field-stimulated release of [3H]noradrena-
line in the rat tail artery. This activity discriminates iron-
dinitrosyl complexes from conventional NO donors and
is apparently NO independent. This finding may have im-
portant implications for inflammatory tissues with non-
heme-iron dinitrosyl species formation.
Materials and Methods
Experimental protocol
A detailed description of the methodology was reported
previously [15]. Briefly, male Wistar rats (12 weeks old)
were killed by cervical dislocation and exsanguinated. A
segment (2–2.5 cm long) of the proximal part of the ven-
tral tail artery was dissected out and kept in oxygenated
(95% O2/5%CO2) medium consisting of (in mM): NaCl
118, KCl 4.8, CaCl2 2.5, KH2PO4 0.9, NaHCO3 25, glu-
cose 11, disodium EDTA 0.03. To prevent rapid decompo-
sition of [3H]noradrenaline, the perfusion medium was
supplemented with 0.3 mM ascorbic acid. The arteries
were cannulated at one end and preincubated for 1 h in
1.5 ml of medium containing 2.2 µM (-)- [3H]noradrena-
line (specific activity 4.4 Ci mmol-1). The arteries were
then suspended vertically (distal end upmost) between
two platinum wire electrodes and perfused by means of a
roller pump with the medium containing 10 µM cocaine
in order to block the re-uptake of released [3H]noradren-
aline. The gaps between the artery and electrodes were
wide enough to allow contraction or relaxation, yet suffi-
ciently narrow enough to stimulate efficiently the intra-
mural nerve terminals. Each artery was subjected to six
stimulation periods. Each stimulation period consisted of
24 monophasic rectangular pulses of 0.3 ms at supramax-
imal strength of 200 mA delivered at 0.4 Hz. The first
stimulation period was applied after 96 min of perfusion
and others followed at 16 min intervals. There were two
initial electrical stimulation periods that were not evaluat-
ed (PS1 and PS2). Collection of the superfusate was started
after 124 min of perfusion in 1-, 2- or 6-min fractions. The
stimulation period at 128 min was termed S1 and subse-
quent ones S2–S4. The stimulation period S2 served as a
control of the stimulation-evoked [3H]noradrenaline re-
lease and vasoconstriction (since the responses were sta-
ble thereafter). The drugs under study or their solvents
were infused in the perfusion medium 8 min before S3.
Infusion took place with a syringe pump at a rate of 17 µL
min-1. At the end of the perfusion period, arteries were
solubilized in 1 ml Soluene-100 (Packard Instrument,
Paris, France). [3H]noradrenaline in the superfusate sam-
ples and in the arteries was measured by liquid scintilla-
tion spectrometry. Under control conditions, the
stimulated [3H]noradrenaline release and vasoconstric-
tion was not changed upon the repeated electrical stimu-
lation. However, the fractional rate of basal
[3H]noradrenaline release declined with time (bn/b2 < b1/
b2; not shown). The [3H]noradrenaline release and peak
of vasoconstriction evoked by S2 amounted to 0.169 ±
0.006 % of total tissue [3H]noradrenaline and 83.8 ± 2.6
mm Hg, respectively (n = 104; all appropriate experiments
pooled).
Solutions and drugs
The drugs used were cocaine hydrochloride (Cooperation
Pharmaceutique Française, Nancy, France), (-)-noradren-
aline hydrochloride, SNP (Sigma, St Louis, USA), Rp-
8pCPT-cGMPS, sodium salt (Biolog, Bremen, Germany).
(-)- [Ring-2,5,6-3H]noradrenaline (specific activity 55.5
Ci mmol-1, New England Nuclear, Dreieich, Germany)
was diluted with unlabelled (-)-noradrenaline hydrochlo-
ride in order to obtain a specific activity of 4.4 Ci mmol-1.
Monomeric forms of DNIC-thiosulfate and DNIC-
cysteine (Fe:ligand molar ratio, 1:20) were synthesised inBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/3
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a Thumberg vessel as described previously [23]. Briefly,
the solutions of FeSO4 7H2O (2 mM) and corresponding
ligand-compound (40 mM) were treated separately with
NO gas (300 mm Hg; 5 min) in oxygen free conditions,
then mixed and evaporated (1 min). The solutions of
DNIC-thiosulfate and DNIC-cysteine were tested by elec-
tron paramagnetic resonance spectroscopy, then frozen
and stored in liquid nitrogen. Fe(II)-thiosulfate complex
was prepared by dissolving FeSO4 7H2O and Na2S2O3
(molar ratio, 1:20) in oxygen free water just before use.
Cys-NO and GS-NO were synthesised as 50 mM solutions
in a Thumberg vessel [23] and stored in liquid nitrogen.
Data analysis
The effects of drugs on the stimulation-evoked [3H]no-
radrenaline release and vasoconstriction were estimated
as the ratio S4/S2. Results are given as mean ± S.E.M. of n
experiments. The Mann-Whitney test was used for com-
parison of mean values. Bonferroni's correction was used
for multiple comparisons to a single control. A P value of
< 0.05 was regarded as significant.
This investigation conforms to authorisation 02816 given
by the French government, Department of Agriculture and
has been conducted in conformity with the Recommenda-
tions from the Declaration of Helsinki and the Guiding
Principles in the Care and Use of Animals.
Acknowledgements
The authors thank Dr. H. Freund, Dr. M. Wendt, J.-F. Poirier and C. Un-
tereiner for their valuable help. This work was supported by European Un-
ion Grant, INTAS and Fondation de la Recherche Médicale.
References
1. Henry Y, Lepoivre M, Drapier JC, Ducrocq C, Boucher JL, Guissani
A:  EPR characterization of molecular targets for NO in
mammalian cells and organelles. FASEB J 1993, 7:1124-1134
2. Kleschyov AL, Muller B, Stoeckel ME, Stoclet JC: Adventitia-de-
rived nitric oxide in rat aortas exposed to endotoxin: cell or-
igin and functional consequences. Am J Physiol heart circ physiol
2000, 279:H2743-H2751
3. Rogers PA, Ding H: L-cysteine-mediated destabilization of din-
itrosyl iron complexes in proteins. J Biol Chem 2001, 276:30980-
30986
4. Bergamini S, Rota C, Canali R, Staffieri M, Daneri F, Bini A, Giovannini
F, Tomasi A, Iannone A: N-acetylcysteine inhibits in vivo nitric
oxide production by inducible nitric oxide synthase. Nitric Ox-
ide 2001, 5:349-60
5. Boese M, Mordvintcev PI, Vanin AF, Busse R, Mülsch A: S-nitrosa-
tion of serum albumin by dinitrosyl-iron complex. J Biol Chem
1995, 270:29244-29249
6. Giannone G, Takeda K, Kleschyov AL: Novel activation of non-se-
lective cationic channels by dinitrosyl-thiosulfate in PC12
cells. J Physiol 2000, 529:735-745
7. Mülsch A, Mordvintcev P, Vanin AF, Busse R: The potent vasodilat-
ing and guanylyl cyclase activating dinitrosyl-iron(II) com-
plex is stored in a protein-bound form in vascular tissue and
is released by thiols. FEBS Lett 1991, 294:252-256
8. Stoclet JC, Troncy E, Muller B, Brua C, Kleschyov AL: Molecular
mechanisms underlying the role of nitric oxide in the cardi-
ovascular system. Exp Opin Invest Drugs 1998, 7:1769-1779
9. Vanin AF, Kleschyov AL: EPR detection and biological implica-
tions of nitrosyl non-heme iron complexes. In: Nitric Oxide in Al-
lograft Rejection and Antitumor Defence 199849-82
10. Stamler JS, Toone EJ, Lipton SA, Sucher NJ: signals: translocation,
regulation, and a consensus motif. Neuron 1997, 18:691-696
11. Gow AJ, Stamler JS: Reactions between nitric oxide and haemo-
globin under physiological conditions. Nature 1998, 391:169-73
12. Bauer PM, Buga GM, Fukuto JM, Pegg AE, Ignarro LJ: Nitric oxide in-
hibits ornithine decarboxylase via S-nitrosylation of cysteine
360 in the active site of the enzyme.  J Biol Chem 2001,
276:34458-34464
13. Buchner E, Gundersen CB: The DnaJ-like cysteine string protein
and exocytotic neurotransmitter release. TINS 1997, 20:223-
227
14. Manalis RS, Cooper GP: Evoked transmitter release increased
by inorganic mercury at frog neuromuscular junction. Nature
1975, 257:690-691
15. Bucher B, Ouedraogo S, Tschöpl M, Paya D, Stoclet JC: Role of the
L-arginine-NO pathway and cyclic GMP in electrical field-in-
duced noradrenaline release and vasoconstriction in the rat
tail artery. Br J Pharmacol 1992, 107:976-982
16. Bredt DS, Snyder SH: Nitric oxide: a physiologic messenger.
Annu Rev Biochem 1994, 63:175-195
17. Egi Y, Matsumura Y, Murata S, Umekawa T, Hisaki K, Takaoka M, Mo-
rimoto S: The effects of NG-nitro-L-arginine, a nitric oxide
synthase inhibitor, on norepinephrine overflow and antidiu-
resis induced by stimulation of renal nerves in anesthetized
dogs. J Pharmacol Exp Ther 1994, 269:529-535
18. Toda N, Yoshida K, Okamura T: Analysis of the potentiating ac-
tion of NG-nitro-L-arginine on the contraction of the dog
temporal artery elicited by transmural stimulation of no-
radrenergic nerves.  Naunyn-Schmiedebergs Arch Pharmacol 1991,
343:221-224
19. Schwarz P, Diem R, Dun NJ, Forstermann U: Endogenous and ex-
ogenous nitric oxide inhibits norepinephrine release from
rat heart sympathetic nerves. Circ Res 1995, 77:841-848
20. Ohlmann P, Martinez MC, Bucher B, Andriantsitohaina R, Muller B,
Schneider F, Stoclet JC: Effect of lipopolysaccharide treatment
on neurogenic contraction and noradrenaline release in rat
arteries. Fundam Clin Pharmacol 2000, 14:593-600
21. Ouedraogo S, Tschöpl M, Stoclet JC, Bucher B: Effects of cyclic
GMP and analogues on neurogenic transmission in the rat
tail artery. Br J Pharmacol 1994, 112:867-872
22. Kanner J, Harel S, Granit R: Nitric oxide as an antioxidant. Arch
Biochem Biophys 1991, 289:130-136
23. Vanin AF, Malenkova IV, Serezhenkov VA: Iron catalyzes both de-
composition and synthesis of S-nitrosothiols: optical and
electron paramagnetic resonance studies.  Nitric Oxide 1997,
1:191-203
24. Bucher B, Pain L, Stoclet JC, Illes P: Role of cyclic AMP in the pre-
junctional alpha-2 adrenoceptor modulation of noradrena-
line release from the rat tail artery. Naunyn Schmiedeberg's Arch
Pharmacol 1990, 342:640-649
25. Gutterman DD: Adventitia-dependent influences on vascular
function. Am J Physiol 1999, 277:H1265-H1272
26. Zhang H, Faber JE: Trophic effect of norepinephrine on arterial
intima-media and adventitia is augmented by injury and me-
diated by different alfa-1-adrenoceptor subtypes.  Circ Res
2001, 89:815-822
27. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF
Jr, Vita JA: Iron chelation improves endothelial function in pa-
tients with coronary artery disease. Circulation 2001, 103:2799-
804